What's Happening?
Tandem Diabetes Care has announced that its t:slim X2 insulin pump, equipped with Control-IQ+ automated insulin delivery technology, has been cleared for use with Eli Lilly's ultra-rapid acting insulin, Lyumjev, in the United States. This approval applies to individuals with type 1 diabetes aged two and above, as well as all adults with type 2 diabetes. The clearance follows a 13-week multicenter study involving 179 participants, which demonstrated high satisfaction and quality of life improvements. The t:slim X2 pump is now compatible with Humalog, Novolog, and Lyumjev U-100 insulins, offering patients more flexibility in managing their diabetes.
Why It's Important?
The approval of the t:slim X2 pump for use with Lyumjev represents a significant advancement in diabetes management, providing patients with more options to tailor their treatment plans. This development is particularly important as it enhances the ability of patients to manage their condition with greater precision and convenience. The collaboration between Tandem Diabetes Care and Eli Lilly underscores the ongoing efforts to improve diabetes care through innovative technology and partnerships. By expanding the compatibility of the t:slim X2 pump, more patients can benefit from advanced insulin delivery systems, potentially improving adherence to treatment and overall health outcomes.
What's Next?
Tandem Diabetes Care and Eli Lilly are continuing their collaboration to secure Lyumjev compatibility for the Tandem Mobi pump. This ongoing partnership aims to further enhance diabetes management options and improve patient outcomes. As the companies work towards expanding the availability of advanced insulin delivery systems, patients can expect more personalized and effective treatment options in the future.
